of functional assays. 1, 2 Using limiting dilution assays, it is possible to detect lymphocytes with specific helper or cytotoxic reactivity at precursor frequencies as low as 1/500 000. 3, 4 Most studies with helper and cytotoxic precursor frequency (HTLPf and CTLPf) assays have focused on compatibility testing of unrelated marrow donors and organ transplant recipients. 3, [5] [6] [7] [8] [9] [10] The assays, which are time consuming and difficult to perform, have limited the popularity of the technique and its wider application. Standard precursor frequency assays have several drawbacks. First, they require large cell numbers. A CTLPf assay, using a 96-well 200 l/well plate, requires approximately 25 ϫ 10 6 stimulator and target cells plus 12 ϫ 10 6 responder cells. 3 The standard HTLPf assay requires 20 ϫ 10 6 stimulator cells and 13 ϫ 10 6 responder cells. 4 The two assays therefore use a total of 45 ϫ 10 6 stimulators and targets, as well as 25 ϫ 10 6 responders. Second, the CTLL-2 (IL-2-dependent) mouse cell line, used to detect HTLP clones at limiting dilution, is notoriously variable in its sensitivity to IL-2. Third, the use of radioactive isotopes for 3 
H uptake and 51
Cr release assays for helper and cytotoxic cell detection adds a further complexity to the procedure. Because of these difficulties, many investigators have chosen to focus solely upon either the HTLPf or the CTLPf assay and there are few data on combined assays in the same individual. 5, 11, 12 In order to address these problems, we developed a combined (split-well) HTLPf and CTLPf assay. The system was miniaturized to make possible a dual HTLPf/CTLPf assay using only 5-10 ml blood from the stimulator and the responder. The read-out of the cytotoxicity and the IL-2 production (helper assay) used Calcein-AM (CAM), a fluorescent dye, in place of radioactive isotopes. Fluorescence is read automatically using a standard Terasaki (HLA typing) plate reader and the precursor frequency is calculated using a computerized program. We describe here the characteristics and potential applications of this improved HTLPf/CTLPf assay.
Materials and methods

Culture media
Unless noted specifically, the medium used for all procedures was RPMI 1640 supplemented with Hepes buffer (10 mm), l-glutamine (2 mm) and gentamicin (0.06 mg/ml). For maintenance of cell line cultures, 10% FCS was added to the supplemented RPMI 1640 (Biofluids, Rockville, MD, USA). For the CTLP/HTLP assays, 10% pooled normal human AB serum (NABS) was added to the supplemented RPMI 1640. For preparation of the target cells, supplemented RPMI 1640 containing 10% FCS was used.
Preparation of PBMC
Peripheral blood was obtained from healthy HLA-matched sibling donors and patients with either CML, AML, myelodysplastic syndrome (MDS) or multiple myeloma (MM) at different stages of disease progression. Mononuclear cells were isolated by density gradient centrifugation (lymphocyte separation medium (LSM) density = 1.077 g/ml, Organon Teknika, Durham, NC, USA). The isolated cells were cryopreserved in a freezing solution of 10% DMSO/20% FCS and stored in the vapor phase of liquid nitrogen. All responder/stimulator pairs (HLA matched and mismatched) were selected from this group of subjects.
Cell line
The IL-2 sensitive cell line, 9.12, was generously donated by Dr Carolyn Keever, Milwaukee, WI. The line was developed by CC-Y Shih.
13 Sensitivity to IL-2 was similar to that found with the standard IL-2-dependent CTLL-2 cell line.
14 The cells were seeded at approximately 10 5 cells in 10 ml supplemented RPMI 1640 plus 1 mm sodium pyruvate, 5 ϫ 10 Ϫ5 m 2-mercaptoethanol (2-ME in thioglycol, 14.3 m, reagent grade, Fisher Scientific, Fair Lawn, NJ, USA), 10% FCS and 7.5% T-STIM Culture Supplement (Collaborative Biomedical Products, Bedford, MA, USA).
Before use in the HTLP assay, the cells were washed twice in medium and resuspended (2 ϫ 10 6 /ml) in 10% FCS/RPMI 1640 with no T-STIM or rhIL-2 (recombinant human IL-2) for 4-6 h. When ready to plate, the cells were washed twice, adjusted to 5 ϫ 10 4 /ml in 10% FCS/RPMI 1640 with 2 X 2-ME and 2 X sodium pyruvate.
The line was restarted every 3 months to avoid cytokine independence. After the new culture was established, the IL-2 sensitivity was confirmed by titration with rhIL-2. Sensitivity was tested at least monthly.
PHA blasts
Peripheral blood mononuclear cells were adjusted to 10 6 /ml in 10% FCS/RPMI 1640. Phytohemagglutinin P (PHA-P; Difco Laboratories, Detroit, MI, USA) was reconstituted and a working solution of 20% in PBS was prepared. Five l/ml of the working solution was added to the PBMC. On day 4, the medium was doubled and additional PHA-P (5 l/ml) was added plus 500 IU/ml rhIL-2 (Tecin, HoffmannLa Roche, Nutley, NJ, USA). On day 6, the cultures were split and fresh medium containing PHA-P and rhIL-2 added. On day 9, the cells were pelleted, evaluated for viability and isolated on Ficoll-Hypaque gradients if viability was less than 80%. Then, PHAB were adjusted to 10 6 /ml in fresh medium with 500 IU/ml rhIL-2 but no PHA-P. On day 10, PHAB were washed and labeled with CAM.
EBV-transformed B-lymphoblastoid cell lines (B-LCL)
To prepare B-LCL, PBMC (5-10 ϫ 10 6 ) were suspended in 20% FCS/RPMI 1640 and EBV supernatant was added. After 1 h incubation, the cells were adjusted to 2 ϫ 10 6 /ml with 20% FCS/RPMI 1640. PHA-P was added and the cells were incubated at 37°C with 5% CO 2 . The next day 1.5 g/ml cyclosporine was added. After 2 weeks the cyclosporine was discontinued. After 1 month, the B-LCL were ready for use.
Calcein-AM
Calcein-AM (CAM) (Molecular Probes, Eugene, OR, USA) is an esterified fluorescent dye which readily enters nucleated cells. The ester linkage disintegrates and the dye is retained by the cells for many hours before slowly leaking from the cell. The excitation and emission wavelengths are 496 and 520 nm, respectively.
For CTLPf assay, target cells were loaded with 10 l CAM per 10 6 cells for 30 min in a 37°C water bath, then washed twice and adjusted to the desired concentration.
For HTLPf assay, the dye was mixed with the bovine hemoglobin quench (FluoroQuench EB Stain-Quench Reagent; One Lambda, Canoga Park, CA, USA) at a concentration of 8 l/ml quench and added to the HTLP assay. The trays were incubated for at least 30 min to allow the dye to penetrate the cells. The fluorescence was then measured in the fluorimeter.
Precursor frequency assay method
The limiting dilution assay is based on the culture of many replicates of a range of responder cell doses in the presence of an excess of stimulating cells. The dose of responder cells was chosen so that a fraction of the wells contained no cytotoxic or helper lymphocyte precursors. After 10 days culture, the wells were assessed for cytotoxic activity with a non-radioactive detection technique, using a Terasaki tray and the vital dye, CAM. 15 The fraction of non-responding wells (no CTLPs/HTLPs) for each responder cell dose was scored. From this the frequency of CTLP/HTLP was calculated using the zero-order term of the Poisson distribution. irradiated stimulator PBMC for HLA-identical pairs and 2 ϫ 10 4 stimulators for HLA-mismatched pairs. There were 24 replicates for each responder concentration. The total volume in each well was 30 l (10 l responders; 20 l stimulators). Stimulators alone were plated for background control. Cells were cultured in RPMI 1640 and 10% heat inactivated NABS. The tightly capped plates were placed in a humidified incubator at 37°C with 5% CO 2 .
HTLPf assay: On day 3, the trays were spun at 130 g and 10 l/well supernatant was transferred to an identical plate to measure IL-2 production (HTLPf). The HTLP trays were kept frozen at Ϫ80°C and then thawed prior to the assay. The 9.12 IL-2-dependent cell line was prepared as described above. Ten microliters (500 cells/well) were added to each well including six wells of 9.12 cells alone. The plates were placed in a humidified incubator at 37°C with 5% CO 2 . After 20 h, 5 l FluoroQuench containing 8 l/ml CAM was dispensed into each well. The trays were incubated for at least 30 min, then spun at 130 g. The fluorescent emission of each well was measured using a Nikon Diaphot 300 inverted fluorescent microscope (Nikon, Tokyo, Japan) controlled by Lambda Scan automated microfluorimeter hardware which includes an automated stage for tray movement and a 'Fluoro Module' that measures the fluorescence (One Lambda). The light source was a 12 V, 100 W halogen lamp. The input light intensity was controlled with neutral density filters. The objective used was a Nikon CF E DL 10 × phase achromat objective, n.a. 0.25. The Lambda Scan Plus software (version 4.2, 1995, customized for CTLP/HTLP assay) converts the fluorescent intensities to numeric values. Wells were scored as positive if the fluorescent emission was more than the mean plus 3 s.d. of the control ('stimulators alone' plus 9.12 cells). The frequency of the responding cells was determined by maximum likelihood estimation using a computer program. Regression analysis was used to generate a straight line, and 2 analysis was used to show that the data were in accordance with single-hit kinetics.
CTLPf assay: After removal of the supernatant for HTLP testing, rhIL-2 (10 l/well) was added to the assay on days 3 and 7 to maintain a concentration of 1.5 IU per well. On day 10, the cultures were assayed for cytotoxicity against CAM-labeled targets from the original stimulator: either PHABs or B-LCL (described previously). 16 PHABs as targets were used in all CTLPf experiments described here except where noted. One to two million target cells were suspended in 1 ml 10% FCS/RPMI 1640. Ten l CAM was added to 1 ml PBS, mixed and added to the cell suspension. After 30 min incubation in a 37°C water bath, the cells were washed twice with RPMI 1640 and resuspended at 10 5 /ml in 10% FCS/RPMI 1640. The plates were spun at 130 g, lightly flicked and the targets plated at 10 l/well. The plates were spun again and incubated for 4 h at 37°C with 5% CO 2 . After incubation, FluoroQuench was added to each well. The plates were spun and the fluorescent emission of each well was measured as described for the HTLPf assay. Wells were scored positive if the fluorescent emission was less than the mean minus 3 s.d. of the background control (stimulators alone plus targets). The frequency of the responding cells was determined by maximum likelihood estimation with the same computer program used for the HTLPf assay. Figure 1 shows the relationship between fluorescent intensity of the 9.12 cell line and rhIL-2 concentration. Results fell within the optimal range of sensitivity of the Lambda Scan system for CAM between 1000 and 5000 units. It was therefore possible to detect IL-2 at concentrations between 0.2 and 2 IU/ml. per well was chosen to be within the optimum range of the fluorescence detector: K562, 500/well; LCL and PHAB, 1000/well; PBL, 2000/well. Figure 3 shows the effect of a measured number of unlabelled PBLs plated in the presence of a fixed number of labelled target cells. Doses of unlabeled cells up to 90 000/well (ratio of labeled to unlabeled, 1:10 000) did not significantly alter emission by stained cells.
Results
Development of the HTLPf assay
Development of the CTLPf assay
Combined CTLPf/HTLPf assay
Results of CTLPf and HTLPf obtained in individual assays are compared with those of the combined split-well assay ( Table 1) . The results of the split well assays fell within the confidence limits of the single assays.
Reproducibility
HTLPf and CTLPf were measured in replicate testing using the same HLA-identical and HLA 6/6 mismatched pairs. A total of five replicates was studied for the HLA-identical pair and nine replicates for the 6/6 HLA-mismatched pair and the assays were repeated on three separate occasions. Results are shown in Table 2 . The CV ranged between 21 and 33% for all CTLP assays and mismatched HTLPf assays. Precision of frequencies lower than 1/400 000 was decreased since the robustness of the test was significantly decreased when 50% or less of the dilutions tested had positive wells.
Detection of HLA disparity
Peripheral blood mononuclear cells were used as stimulators to test a range of HLA diverse responder/stimulator combinations. HLA identity was determined by serology for HLA class I (HLA-A and HLA-B loci) and DNA sequence-specific polymorphism for HLA class II (HLA DR␤1 locus). Three groups were evaluated: (1) mismatched, unrelated individuals: responder and stimulator expressed no HLA class I or class II antigens in common (n = 7); (2) partiallymatched individuals: responder and stimulator shared 3/6 HLA antigens (n = 9); (3) matched, related bone marrow donors and their HLA-identical sibling recipients (n = 9). Results are shown in Figure 4a and b. Both the HTLPf and CTLPf assays showed a trend to higher frequencies with increasing HLA disparity and discriminated between 3/6 and 0/6 matched pairs. Compared with CTLPf, more HTLPf-mismatched pairs showed frequencies overlapping with the HLA-identical siblings. In contrast, the range of results for HLA-identical siblings was much greater in the HTLPf assay than the CTLPf assay which suggests a greater ability of the HTLPf to discriminate between different degrees of matching in the HLA-identical sibling pairs. Figure 5 compares HTLPf with CTLPf pairs with different degrees of HLA identity. HTLPf and CTLPf were compared in nine HLA-identical sibling pairs, nine 3/6 HLAmismatched pairs and seven 0/6 HLA-mismatched pairs. There was no significant correlation between HTLPf and CTLPf indicating that the two assays measured independent variables. 
Correlation between HTLPf and CTLPf
Coincidence of helper and cytotoxic reactivity at limiting dilution
In order to determine the T cell subsets responsible for helper and cytotoxic activity, three split-well assays were performed using a mismatched responder/stimulator pair. A single source of 50 Gy irradiated PBMC were used as stimulators. PHAB derived from the stimulator were used as CTLP targets. Responders were either unmanipulated PBMC, CD8-depleted (CD4 enriched, Ͻ3% CD8 + ) PBMC or CD4-depleted (CD8 enriched, Ͻ1% CD4 + ) PBMC. Results are shown in Figure 6 . The unmanipulated responses gave precursor frequencies of 1/4939 (HTLPf) and 1/38 232 (CTLPf). CD4 depletion revealed a residual population of HTLP with a comparable frequency for the CTLP. In contrast, the CD8 depletion completely abrogated the CTLP but conserved and enriched the helper population. These results indicated that no cytotoxic CD4 cells were detected but that the CD8 fraction contained both CTLP and HTLP. To determine whether such cells had combined or separate helper and cytotoxic functions, we examined the coincidence of CTLP and HTLP in individual wells. Figure 7 shows the results of a representative assay indicating that some CD8 responders showed helper activity, some cytotoxic activity and some combined activities. In contrast the CD4 cell fraction showed only helper activity.
Discussion
To assess the sensitivity of the fluorescent technique for the HTLP assay, we first demonstrated that the technique was sufficiently sensitive to detect the IL-2 doses typically found at limiting dilution (0.5 IU/ml).
14 For the 9.12 cell line, a dose of 500 cells/well was chosen because it allowed the full range of the detector sensitivity to be utilized.
For CTLP targets, we found that due to cell size variations different cell numbers were required for optimum discrimination between lysed and non-lysed cells; however, the range was not extensive: for most targets 500-1000 cells/well was adequate, but for PBL 1500-2000 cells/well was preferable. For both assays, the discrimination between positive and negative wells fell within the limits of tolerance of fluorescent detection. Replicate tests showed overall acceptable reproducibility (CV approximately 30%). There are no comparable quality control studies previously reported. Deacock et al 14 described one HTLPf assay done in quadruplicate with fairly consistent results. Variations are to be expected in this complicated bioassay and this issue has been addressed by Deacock et al. Furthermore, the split-well assay approach did not alter either HTLP or CTLP results. We also found that the HTLPf and CTLPf results were comparable to those obtained in earlier standard radioisotope-based assays using the same stimulator/responder pairs (data not shown). The choice of target cell (B-LCL or PHAB) did not appear to be critical for HLA-mismatched pairs. However, for HLA-identical pairs, the use of B-LCL targets sometimes resulted in very high precursor frequencies which were not seen when PHAB targets were used (see Table 1 ). This effect was believed to be the response of memory T cell clones against EBV presented by the B-LCL. 17 On testing different stimulator/responder pairs, we found the expected difference in frequency between HLAmatched and -mismatched pairs. Comparison of CTLPf and HTLPf within the same stimulator/responder pair showed no correlation in either the matched or mismatched sets. Therefore, a combined assay might provide additional information that could refine determination of the prediction of clinical outcome after unrelated BMT. 5, 11, 12 To further investigate the relationship between HTLPf and CTLPf, we examined the coincidence of HTLP and CTLP precursors in the same well. We argued that wells with both HTLP and CTLP activity could represent either multiple helper and cytotoxic clones or single clones with both helper and cytotoxic activity. Results in Figure 7 showed that coincident wells occurred even at limiting dilution suggesting the presence of single precursors with helper and cytotoxic potential. To better define the nature of such wells we carried out CTLP and HTLP assays on a single sample which was either depleted of CD4 cells, CD8 cells or left intact. These experiments showed that while no CD4 precursors had cytotoxic activity, some CD8 had both cytotoxic and helper activity. It therefore seems likely that the combined assay can detect at least three classes of cells: CD4 + helpers, cytotoxic CD8 + T cells and CD8 + cells producing IL-2. These results do not exclude the ability of this assay to detect cytotoxic CD4 cells as has been previously described. 18 The combined assay used only 5 ϫ 10 6 stimulators and 2 ϫ 10 6 responders. This represents a 10-and 12-fold reduction (respectively) in the number of cells required for the two separate assays. 5, 11, 12 Assuming a normal number of circulating lymphocytes, it is therefore possible to carry out the combined assay using only 5-10 ml of peripheral blood from stimulators and responders. This fact, and the ease of performing the assay should facilitate sequential studies of lymphocyte precursor frequency: for example, after marrow stem cell allografting or for monitoring immune responses after adoptive transfer of lymphocytes to treat relapse, or virus reactivation. [19] [20] [21] [22] Furthermore, the technique should lend itself to the development of antigenspecific T cell responses. For example, we are now investigating HTLPf and CTLPf against peptides derived from proteinase-3 which may be a myeloid leukemiaspecific protein target of alloresponses after BMT. 23 Finally, although combined assays for HTLPf and CTLPf have previously been described, 5, 11, 12 the miniaturization of the technique reduces considerably the expense in materials and the avoidance of radioactive reagents facilitates its application in the laboratory. Most previous reported frequencies utilize radioisotopes. The technique of Bouma et al employs europium release. 5 This technique requires specialized time-resolved fluorescence instrumentation for the read-out and the results are often difficult to interpret. Our technique uses familiar fluorescence detection devices and the fluorescent dye technique is simple and straight-forward. While the wells can be read visually using an inverted fluorescent microscope, the use of the Terasaki (HLA-typing) plate permits its easy adaptation to an automated fluorescent detection device such as the Lambda FluoroScan or a fluorescent ELISA reader linked con- Cells/well x 103 CD4+CD8 CD4 depleted CD4 depleted a b c Figure 6 Helper and cytotoxic function of T cell subsets. PBMC from a 6/6 mismatched responder/stimulator were tested. HLA types: (R) A1, 30; B8; DR11, 17 (S) A2, 11; B35, 58; DR3, 13. Responders were either unmanipulated CD4+ CD3 cells (a), CD4 depleted (b), or CD8 depleted (c). Target was PHAB. CD4 depletion conserved helper function in the CD8 subsets whereas CD8 depletion conserved helper activity but abrogated cytotoxic activity. Open circles (ć) represent HTLP doses while closed circles (b) are CTLP doses. veniently to a computer interface, permitting automatic computation of precursor frequencies.
